Radiodermatitis Market by Product (Topical, Oral Drugs, and Dressings) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2019-2027
- ALL4059017
- 213 Pages
- August 2020
- Healthcare
Radiodermatitis is a cutaneous reaction that occurs as one of the side effects of radiotherapy during cancer treatment or sometimes after interventional radiology. It is one of the most common side effects of radiation therapies used in carcinoma mostly for breasts, head & neck tumors, lungs, and soft tissue sarcomas. According to an article published in the American Journal of Clinical Dermatology in 2016, it is estimated that 95% of cancer patients receiving radiation therapy would develop some form of radiodermatitis, including erythema, dry desquamation, and moist desquamation. Radiodermatitis can further be classified as acute and chronic. Acute radiation dermatitis occurs within 90 days of exposure to radiation.
Chronic radiodermatitis is an extension of acute process and involves further inflammatory changes in skin. The onset of chronic radiation dermatitis may occur from 15 days to 10 years or more after the beginning of a radiation therapy and can be characterized by:
Disappearance of follicular structures
Increase in collagen and damage to elastic fibers in the dermis
Fragile surface skin (epidermis)
Telangiectasia (prominent blood vessels).
Growth of the global radiodermatitis market is majorly driven by increase in prevalence of cancer and rise in adoption of radiotherapy for treatment globally. Furthermore, increase in geriatric population also fuels growth of the radiodermatitis market. However, high cost associated with radiodermatitis treatment is anticipated to restrict growth of the market. On the contrary, increase in demand for reduction of side effects associated with radiation therapy is expected to offer lucrative opportunities for the market expansion during the forecast period.
The global radiodermatitis market is segmented into product, distribution channel, and region. On the basis of product, the market is fragmented into topical, oral drugs, and dressings. The topical products segment is further divided into corticosteroids, hydrophilic creams, topical antibiotics, and others. The dressings segment is divided into hydrogel and hydrocolloid dressings, no sting barrier film, honey impregnated gauze, silicone coated, and others. By distribution channel, it is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify prevailing opportunities along with strategic assessment of the global radiodermatitis market.
Market size and estimations are based on a comprehensive analysis of end users, developments, and services in the industry.
An in-depth analysis based on region assists to understand the regional market and facilitates strategic business planning.
Developmental strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Product
• Topical
o Corticosteroids
o Hydrophilic Creams
o Topical Antibiotics
o Others
• Oral Drugs
• Dressings
o Hydrogel and Hydrocolloid Dressings
o No Sting Barrier Film
o Honey Impregnated Gauze
o Silicone Coated
o Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Australia
o Japan
o India
o China
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
• 3M COMPANY
• BAUSCH HEALTH COMPANIES INC
• BAYER AG
• BMG PHARMA SPA
• CONVATEC GROUP PLC
• GLAXOSMITHKLINE PLC
• HELSINN HEALTHCARE SA
• MOLNLYCKE HEALTH CARE
• MYLAN N.V.
• SMITH & NEPHEW PLC
• STRATPHARMA AG
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.1.Top winning strategies
3.4.Top player positioning, 2019
3.5.Porter’s five forces analysis
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Growth in the geriatric population
3.6.1.2.Increase in prevalence of cancer
3.6.1.3.Rise in the adoption of radiotherapy
3.6.2.Restraints
3.6.2.1.Higher radiodermatitis cost
3.6.3.Opportunity
3.6.3.1.Increase in demand for reduction of side effects associated with radiation therapy
3.7.COVID-19 impact analysis for radiodermatitis market
3.8.Reimbursement scenario
3.9.Approved radiodermatitis products with prices
3.10.Pipeline analysis
CHAPTER 4:GLOBAL RADIODERMATITIS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Topical
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Corticosteroids
4.2.2.1.1.Market size and forecast
4.2.2.2.Hydrophilic creams
4.2.2.2.1.Market size and forecast
4.2.2.3.Topical antibiotics
4.2.2.3.1.Market size and forecast
4.2.2.4.Others
4.2.2.4.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Oral drugs
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Dressings
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Hydrogel and hydrocolloid dressings
4.4.2.1.1.Market size and forecast
4.4.2.2.No sting barrier film
4.4.2.2.1.Market size and forecast
4.4.2.3.Honey impregnated gauze
4.4.2.3.1.Market size and forecast
4.4.2.4.Silicone coated
4.4.2.4.1.Market size and forecast
4.4.2.5.Others
4.4.2.5.1.Market size and forecast
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
CHAPTER 5:RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital pharmacy
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Retail pharmacy
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online pharmacy
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:GLOBAL RADIODERMATITIS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S. radiodermatitis market, by product
6.2.2.2.U.S. radiodermatitis market, by distribution channel
6.2.2.3.Canada radiodermatitis market, by product
6.2.2.4.Canada radiodermatitis market, by distribution channel
6.2.2.5.Mexico radiodermatitis market, by product
6.2.2.6.Mexico radiodermatitis market, by distribution channel
6.2.3.North America radiodermatitis market, by product
6.2.4.North America Radiodermatitis Market, by distribution channel
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany radiodermatitis market, by product
6.3.2.2.Germany radiodermatitis market, by distribution channel
6.3.2.3.France radiodermatitis market, by product
6.3.2.4.France radiodermatitis market, by distribution channel
6.3.2.5.UK radiodermatitis market, by product
6.3.2.6.UK radiodermatitis market, by distribution channel
6.3.2.7.Italy radiodermatitis market, by product
6.3.2.8.Italy radiodermatitis market, by distribution channel
6.3.2.9.Spain radiodermatitis market, by product
6.3.2.10.Spain radiodermatitis market, by distribution channel
6.3.2.11.Rest of Europe radiodermatitis market, by product
6.3.2.12.Rest of Europe radiodermatitis market, by distribution channel
6.3.3.Europe radiodermatitis market, by product
6.3.4.Europe radiodermatitis market, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan radiodermatitis market, by product
6.4.2.2.Japan radiodermatitis market, by distribution channel
6.4.2.3.China radiodermatitis market, by product
6.4.2.4.China radiodermatitis market, by distribution channel
6.4.2.5.India radiodermatitis market, by product
6.4.2.6.India radiodermatitis market, by distribution channel
6.4.2.7.Australia radiodermatitis market, by product
6.4.2.8.Australia radiodermatitis market, by distribution channel
6.4.2.9.South Korea radiodermatitis market, by product
6.4.2.10.South Korea radiodermatitis market, by distribution channel
6.4.2.11.Rest of Asia-Pacific radiodermatitis market, by product
6.4.2.12.Rest of Asia-Pacific radiodermatitis market, by distribution channel
6.4.3.Asia-Pacific radiodermatitis market, by product
6.4.4.Asia-Pacific radiodermatitis market, by distribution channel
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil radiodermatitis market, by product
6.5.2.2.Brazil radiodermatitis market, by distribution channel
6.5.2.3.Saudi Arabia radiodermatitis market, by product
6.5.2.4.Saudi Arabia radiodermatitis market, by distribution channel
6.5.2.5.South Africa radiodermatitis market, by product
6.5.2.6.South Africa radiodermatitis market, by distribution channel
6.5.2.7.Rest of LAMEA radiodermatitis market, by product
6.5.2.8.Rest of LAMEA radiodermatitis market, by distribution channel
6.5.3.LAMEA radiodermatitis market, by product
6.5.4.LAMEA radiodermatitis market, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.THE 3M COMPANY
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BAYER AG.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.BAUSCH HEALTH COMPANIES INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.BMG PHARMA S.P.A.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.5.CONVATEC GROUP PLC.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.GLAXOSMITHKLINE PLC
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.7.HELSINN HEALTHCARE SA
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments
7.8.MOLNLYCKE HEALTH CARE AB
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.MYLAN N.V.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.STRATPHARMA AG
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments
7.11.SMITH & NEPHEW PLC
7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
TABLE 01.SEVERITY OF RADIATION DERMATITIS, BY GRADES
TABLE 02.APPROVED RADIODERMATITIS PRODUCT WITH PRICES
TABLE 03.PIPLINE ANALYSIS
TABLE 04.RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 05.RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 06.RADIODERMATITIS MARKET FOR TOPICAL, BY TYPE, 2019–2027 ($MILLION)
TABLE 07.RADIODERMATITIS MARKET FOR TOPICAL, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 08.RADIODERMATITIS MARKET FOR TOPICAL, BY REGION, 2019–2027 ($MILLION)
TABLE 09.RADIODERMATITIS MARKET, FOR TOPICAL, BY REGION, 2019–2027 (MILLION UNITS)
TABLE 10.RADIODERMATITIS MARKET FOR ORAL DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 11.RADIODERMATITIS MARKET FOR ORAL DRUGS, BY REGION, 2019–2027 (MILLION UNITS)
TABLE 12.RADIODERMATITIS MARKET FOR DRESSINGS, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.RADIODERMATITIS MARKET FOR DRESSINGS, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 14.RADIODERMATITIS MARKET, FOR DRESSING, BY REGION, 2019–2027 ($MILLION)
TABLE 15.RADIODERMATITIS MARKET FOR DRESSINGS, BY REGION, 2019–2027 (MILLION UNIT)
TABLE 16.RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 17.RADIODERMATITIS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 18.RADIODERMATITIS MARKET FOR RETAIL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 19.RADIODERMATITIS MARKET FOR ONLINE PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 20.RADIODERMATITIS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 21.RADIODERMATITIS MARKET, BY REGION, 2019–2027 (MILLION UNITS)
TABLE 22.NORTH AMERICA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 24.U.S. RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 25.U.S. RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 26.U.S. RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 27.CANADA RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 28.CANADA RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 (MILLION UNITS)
TABLE 29.CANADA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 30.MEXICO RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 31.MEXICO RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 (MILLION UNITS)
TABLE 32.MEXICO RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 33.NORTH AMERICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 34.NORTH AMERICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 35.NORTH AMERICA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 36.EUROPE RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 37.EUROPE RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 38.GERMANY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 39.GERMANY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 40.GERMANY RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 41.FRANCE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 42.FRANCE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 43.FRANCE RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 44.UK RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 45.UK RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 46.UK RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 47.ITALY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 48.ITALY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 49.ITALY RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.SPAIN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 51.SPAIN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 52.SPAIN RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 55.REST OF EUROPE RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 56.EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 57.EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 58.EUROPE RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 61.JAPAN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 62.JAPAN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 63.JAPAN RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 64.CHINA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 65.CHINA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 66.CHINA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 67.INDIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 68.INDIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 69.INDIA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 70.AUSTRALIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 71.AUSTRALIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 72.AUSTRALIA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 73.SOUTH KOREA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 74.SOUTH KOREA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 75.SOUTH KOREA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 78.REST OF ASIA-PACIFIC RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 80.ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 81.ASIA-PACIFIC RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 82.LAMEA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 83.LAMEA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 84.BRAZIL RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 85.BRAZIL RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 86.BRAZIL RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 87.SAUDI ARABIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 88.SAUDI ARABIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 89.SAUDI ARABIA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 90.SOUTH AFRICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 91.SOUTH AFRICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 92.SOUTH AFRICA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 93.REST OF LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 94.REST OF LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 95.REST OF LAMEA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 96.LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 97.LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 98.LAMEA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 99.3M: COMPANY SNAPSHOT
TABLE 100.3M: OPERATING SEGMENTS
TABLE 101.3M: PRODUCT PORTFOLIO
TABLE 102.BAYER: COMPANY SNAPSHOT
TABLE 103.BAYER: OPERATING SEGMENTS
TABLE 104.BAYER: PRODUCT PORTFOLIO
TABLE 105.BAUSCH: COMPANY SNAPSHOT
TABLE 106.BAUSCH: OPERATING SEGMENTS
TABLE 107.BAUSCH: PRODUCT PORTFOLIO
TABLE 108.BMG PHARMA: COMPANY SNAPSHOT
TABLE 109.BMG PHARMA: OPERATING SEGMENTS
TABLE 110.BMG PHARMA: PRODUCT PORTFOLIO
TABLE 111.CONVATEC: COMPANY SNAPSHOT
TABLE 112.CONVATEC: OPERATING SEGMENTS
TABLE 113.CONVATEC: PRODUCT PORTFOLIO
TABLE 114.GSK: COMPANY SNAPSHOT
TABLE 115.GSK: OPERATING SEGMENTS
TABLE 116.GSK: PRODUCT PORTFOLIO
TABLE 117.HELSINN: COMPANY SNAPSHOT
TABLE 118.HELSINN: OPERATING SEGMENTS
TABLE 119.HELSINN: PRODUCT PORTFOLIO
TABLE 120.MOLNLYCKE: COMPANY SNAPSHOT
TABLE 121.MOLNLYCKE: OPERATING SEGMENTS
TABLE 122.MOLNLYCKE: PRODUCT PORTFOLIO
TABLE 123.MYLAN: COMPANY SNAPSHOT
TABLE 124.MYLAN: OPERATING SEGMENTS
TABLE 125.MYLAN: PRODUCT PORTFOLIO
TABLE 126.STRATPHARMA: COMPANY SNAPSHOT
TABLE 127.STRATPHARMA: OPERATING SEGMENTS
TABLE 128.STRATPHARMA: PRODUCT PORTFOLIO
TABLE 129.SMITH & NEPHEW: COMPANY SNAPSHOT
TABLE 130.SMITH & NEPHEW: OPERATING SEGMENTS
TABLE 131.SMITH & NEPHEW: PRODUCT PORTFOLIO
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
